Ionis Pharmaceuticals INC Form 4 insider transactions

Ionis Pharmaceuticals Director Joseph Klein III sold 28,000 shares of common stock for $60.00 per share after exercising stock options, as part of a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals' EVP, Chief Development Officer Richard S. Geary, sold 10,000 shares of common stock for approximately $50.37 per share under a pre-arranged trading plan.

Ionis Pharmaceuticals' EVP, Chief Human Resources Officer, Shannon L. Devers, exercised stock options and subsequently sold a portion of common stock.

Ionis Pharmaceuticals director Joseph H. Wender sold 28,000 shares of common stock in early September 2025 under a pre-arranged 10b5-1 trading plan.

Joseph Baroldi, EVP and Chief Business Officer of Ionis Pharmaceuticals, executed a series of stock option exercises and subsequent share sales under a pre-arranged trading plan.

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, executed pre-planned stock option exercises and subsequent sales of common stock.

Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, executed planned sales of common stock following the exercise of stock options.

Ionis Pharmaceuticals Director Joseph Loscalzo exercised stock options and subsequently sold 16,000 shares of common stock for a profit, as per a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals' EVP, Chief Clinical Development Officer, Eugene Schneider, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, acquired 331 shares of common stock through an employee stock purchase plan.

Ionis Pharmaceuticals CEO Brett Monia acquired 189 shares of common stock at $27.71 per share through an employee stock purchase plan.

Ionis Pharmaceuticals' EVP, Chief Development Officer Richard S. Geary, acquired 165 shares of common stock at $27.71 per share through an employee stock purchase plan.

Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, acquired 213 shares of common stock through an employee stock purchase plan.

Ionis Pharmaceuticals' EVP, Brian Birchler, acquired 166 shares of common stock through an employee stock purchase plan.

Ionis Pharmaceuticals Director Allene M. Diaz sold 1,427 shares of common stock for approximately $42.53 per share under a pre-arranged trading plan.

C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, exercised stock options and sold 10,000 shares of common stock on August 18, 2025, according to a Form 4 filing.

Ionis Pharmaceuticals Director B. Lynne Parshall sold 5,000 shares of common stock on August 6, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Ionis Pharmaceuticals' EVP, Chief Development Officer Richard S. Geary, sold 10,000 shares of common stock for approximately $428,593 pursuant to a pre-arranged trading plan.

Ionis Pharmaceuticals' EVP, Chief Clinical Development Officer, Eugene Schneider, sold 9,549 shares of common stock for approximately $42.80 per share.

Ionis Pharmaceuticals CEO Brett P. Monia executed a pre-arranged sale of 2,432 shares of common stock at $45 per share after exercising options.

Ionis Pharmaceuticals Director Joseph Loscalzo acquired 4,079 shares of common stock through the vesting of Restricted Stock Units, increasing his direct beneficial ownership to 36,330 shares.

Ionis Pharmaceuticals Director Michael J. Yang increased his direct ownership of company common stock by 4,079 shares following the vesting of Restricted Stock Units.

Ionis Pharmaceuticals Director Joseph H. Wender acquired 4,079 shares of common stock on July 15, 2025, through the vesting of Restricted Stock Units.

Ionis Pharmaceuticals Director B. Lynne Parshall acquired 4,079 shares of common stock through the vesting and conversion of Restricted Stock Units.

Ionis Pharmaceuticals Director Joan E. Herman reported the acquisition of 4,079 shares of common stock through the vesting of Restricted Stock Units on July 15, 2025, increasing her direct beneficial ownership to 46,086 shares.

Ionis Pharmaceuticals Director Michael R. Hayden acquired 4,079 shares of common stock through the vesting of Restricted Stock Units, increasing his direct beneficial ownership to 54,298 shares.

Ionis Pharmaceuticals director Allene M. Diaz acquired 4,079 shares of common stock through the vesting of Restricted Stock Units, increasing her direct beneficial ownership.

Ionis Pharmaceuticals Director Spencer R. Berthelsen acquired 4,079 shares of common stock on July 15, 2025, through the vesting of a Restricted Stock Unit award.

Ionis Pharmaceuticals CEO Brett P. Monia sold 1,160 shares of common stock for a weighted average price of $41.7381 per share on July 11, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Ionis Pharmaceuticals Director Michael J. Yang was granted 11,518 non-qualified stock options and 5,220 restricted stock units on July 1, 2025, as part of the company's non-employee director compensation policy.